A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) [Oblimersen] Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies

Trial Profile

A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) [Oblimersen] Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Docetaxel; Oblimersen
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top